Lasalocid Premix Veterinary Grade API is a fermentation-derived polyether carboxylic acid ionophore supplied as the sodium salt of lasalocid A, CAS 25999-20-6, molecular formula C34H53NaO8, and molecular weight 612.77 g/mol. The powder is white to off-white, crystalline, practically insoluble in water, and soluble in chlorinated hydrocarbons, methanol, and ethyl acetate. The grade is intended for further manufacture into tablets, capsules, oral powders, granules, feed premixes, non-aqueous injections, and solutions. Available concentration designations include the ≥95% w/w dry-basis API powder, water-dispersible granules at 10% and 20% active strength, and feed premixes at 10–20% lasalocid sodium on a suitable carrier. The raw material lots used for dosage-form manufacture differ from feed-only premixes in residual solvent control, microbial limits, and documentation required for GMP processing.

What distinguishes the veterinary-grade API from a feed-only lasalocid premix, and how does that change release testing?

Feed-grade lasalocid premixes are released against carrier identity and drug concentration uniformity in feed, while the veterinary API grade is released with tighter limits for assay, related substances, moisture, residue on ignition, residual solvents, and microbiological burden. Table 1 presents representative release criteria used by GMP manufacturers of veterinary lasalocid sodium; named compendial monographs or registration dossiers may set different limits. These values are shown as typical release limits rather than universal regulatory limits because purification route and intended dosage form influence the acceptable residual solvent profile and endotoxin threshold.

Oral powders and feed premixes are the most demanding operations for blend uniformity because the final feed drug concentration can be as low as 75–125 mg/kg in broiler feeds and 25–30 g/ton dry matter in cattle feeds, depending on regional authorization. A direct mix of the ≥95% API into final feed is not used at production scale; instead, a four-step dilution is employed: API into a carrier premix at 10–20%, then into an intermediate concentrate, then into the final feed batch. Ribbon blenders with paddle-tip clearances of 5–10 mm and plough mixers fitted with high-speed choppers provide the shear needed to disperse the electrostatic API. Batch-to-batch variation is assessed by taking 10–20 thief samples per blend and analyzing lasalocid content by HPLC; acceptance limits of ±15% relative to target are commonly applied to premix blends, while final feed registration may impose narrower in-use limits. When the carrier has a bulk density below 0.30 g/mL or the API is not pre-sieved through a 600 µm screen, segregation increases and the blend can drift outside the limit during transfer to packaging or silo storage.

Water-dispersible granules for oral dosing are produced by wet granulation of the API with lactose, povidone, and a disintegrant such as crospovidone. The granules must pass a 710 µm sieve and disintegrate in water at 20 °C within 5 min; however, because lasalocid sodium is not truly soluble, the resulting liquid is a suspension, not a solution. Suspension stabilizers such as xanthan gum at 0.1–0.3% w/v prevent rapid settling. A preparation labelled as an oral solution therefore contains a co-solvent or micellar system rather than simple water.

Cation-selectivity differences between lasalocid and monovalent ionophores

The primary structural difference is the ion-binding cavity. Lasalocid forms neutral complexes with both monovalent and divalent cations, particularly calcium and barium, whereas monensin and salinomycin are more monovalent-selective. This broader complexation has two practical consequences. First, calcium-containing excipients, such as dicalcium phosphate dihydrate in tablet matrices or hard water used for oral suspensions, can reduce free lasalocid availability if the sodium ion is displaced. Second, the toxicity profile and species sensitivity are not identical to monensin; horses remain highly sensitive to all ionophores, but the severity of exposure and the dose–response slope differ between molecules. Table 2 summarises comparative properties relevant to formulation and handling.

Compared with synthetic coccidiostats such as triazine derivatives, lasalocid acts rapidly on extracellular sporozoites and early merozoites; its primary target is cation flux across the cell membrane rather than nuclear division. This gives a different resistance-management profile and may preserve susceptibility to synthetic drugs in rotation programs. The broader divalent cation binding of lasalocid means that calcium-rich feed matrices or hard water can alter the apparent free drug concentration, whereas monovalent-selective ionophores are less affected by calcium but more affected by potassium status. These differences should be recorded in the formulation development report when changing from one ionophore to another.

When capsule and tablet operations are scaled from laboratory powder blends

For tablet and capsule manufacture, the crystalline API powder frequently has poor flow and exhibits electrostatic adhesion to metal and polymer contact surfaces. Direct compression is not the default route for lasalocid sodium; dry granulation by roller compaction or wet granulation with a non-aqueous binder is preferred. The particle size target is set by the dosage form: suspension-grade powder for oral solutions or drench concentrates is often controlled to D₉₀ ≤ 50 µm by air-jet milling, whereas tablet grades may accept D₉₀ ≤ 150 µm after granulation. Bulk density after compaction should be positioned above 0.45 g/mL to prevent hopper bridging. During capsule filling with dosator nozzles, the pin height is adjusted to deliver a fill weight variation below 5%; the API blend must be conditioned to 40–50% RH to reduce surface charge. Magnesium stearate is used at 0.5–1.0% w/w only after the API has been pre-blended because hydrophobic lubricants can coat lasalocid crystals and slow dissolution in non-aqueous release media.

For injectable formulations, the solvent system rather than the API purity becomes the controlling variable

When a solution or injectable dosage form is required rather than a dry premix, the formulation approach must account for the low aqueous solubility of lasalocid sodium. The dry substance is practically insoluble in water, so aqueous vehicles alone cannot dissolve a therapeutic dose without pH adjustment or organic co-solvent. Non-aqueous vehicles such as propylene glycol, N-methyl-2-pyrrolidone, glycerol formal, or medium-chain triglycerides can be used as primary solvents; water is then introduced only in a proportion that does not precipitate the free acid or sodium salt. Buffered systems are maintained between pH 7.5 and 9.0 to keep the ionisable carboxylate in its sodium form; below pH 6.0, the free acid may precipitate as a sticky residue on vessel walls and filter membranes. Because lasalocid is a polyether ionophore, it can complex calcium and magnesium ions present in water or glassware leachates, so chelating agents such as edetate disodium are sometimes added at 0.01–0.05% w/v in injectable preparations. Long-term stability data for ready-to-use injectable lasalocid solutions are limited; published data for this specific configuration is limited, so each compounded formulation should be evaluated for precipitation, assay retention, and subvisible particle formation at 2–8 °C and 25 °C over the intended shelf life.

Controlling thermal and moisture exposure during feed pelleting

Feed pelleting exposes the API to conditioner temperatures of 70–90 °C with retention times of 30–120 s, followed by compression through die bores. Polyether ionophores are generally stable enough for pelleting, but the recovery of lasalocid depends on the carrier and the moisture profile. Dry calcium carbonate or wheat middling carriers typically show less than 5% assay loss at 80 °C, while molasses-containing premixes can produce higher losses if free moisture exceeds 12%. The proposed mechanism is acid-catalysed or water-mediated opening of the polyether ring, not sublimation of the parent drug. Facilities that pellet feed containing lasalocid should therefore validate the conditioning temperature, moisture, and die throat pressure using HPLC assay before and after pelleting. Process controls include limiting molasses to 2–3% in the premix, drying the carrier to ≤10% moisture, and avoiding steam-conditioner dwell times above 120 s. Cross-contamination protocols require flushing with ground corn or wheat bran after every lasalocid batch when equine feed is produced on the same line.

Regulatory dossiers for lasalocid-containing dosage forms reference the feeding and residue standards of the intended market. In the United States, approved lasalocid use in animal feeds is codified in 21 CFR 558.311; the regulation specifies species, use levels, and withdrawal periods. In the European Union, lasalocid sodium is authorised as a feed additive under the additives regulation, with maximum residue limits and marker residue definitions set through the veterinary medicinal product legislation; the substance may not be administered to laying hens producing eggs for human consumption in some Member States unless specifically authorised. For the API itself, residual solvent control follows USP <467> or Ph. Eur. 2.4.24, elemental impurity control follows USP <232>/<233> or Ph. Eur. 2.4.8, and microbiological examination follows USP <61>/<62> or Ph. Eur. 2.6.12/2.6.13. Certificates of analysis should include the batch number, date of manufacture, retest date, storage temperature, and the calibration status of the HPLC system used for assay.

Operational boundaries are set by the toxicology of polyether ionophores, not solely by the physical particle. Lasalocid sodium is not intended for equine species; even trace carryover from a medicated feed line can be fatal to horses. Dedicated equipment or validated flush sequences are required when the same mixer produces equine feed. Concurrent oral administration of tiamulin or certain macrolide antibiotics can reduce ionophore clearance and increase the risk of cardiac and skeletal muscle toxicity; the interaction is most thoroughly documented for monensin, but lasalocid should likewise be managed by a veterinarian and not co-administered unless authorized by the marketing authorisation. Dust control is mandatory: the powder should be handled with local exhaust ventilation and respiratory protection because respirable ionophore dust is a cardiac hazard. Storage should be in tightly closed containers at 15–25 °C and protected from light and moisture. When moisture uptake exceeds 5%, caking and surface hydrolysis can occur on prolonged storage. Compounded oral suspensions should be prepared immediately before use or stabilised by a validated suspending system because the API settles rapidly and can adhere to polyethylene dosing syringes if the pH is outside 7.5–9.0.